Background {#Sec1}
==========

Patients with acute coronary syndrome (ACS) are diverse in terms of clinical presentation and risk of death or disability. Accurate management decisions with comprehensive evaluation may improve the outcomes of patients at high risk. To identify high-risk patients, current guidelines recommend a standardized approach involving validated scoring systems such as the Global Registry of Acute Coronary Events (GRACE) score \[[@CR1]--[@CR3]\]. Although the GRACE risk score has been validated, the score does not include measurement of important biomarkers. Therefore, whether combining other biomarkers with the GRACE score can provide a more accurate risk estimation in ACS needs to be explored.

Long-term glycometabolic disorder implies high risk for cardiovascular disease \[[@CR4], [@CR5]\]. Glycosylated hemoglobin (HbA1c) is a well-known biomarker of long-term glycometabolic state and is minimally affected by stress during ACS. Previous research found elevated HbA1c content related to increased risk of cardiovascular events \[[@CR6]--[@CR8]\].

In the present study, we investigated the predictive value of HbA1c content and GRACE score individually for major adverse cardiac events (MACEs) in patients with ACS but without diabetes mellitus (DM) undergoing PCI and the potential incremental prognostic value of HbA1c content added to GRACE score.

Methods {#Sec2}
=======

Study cohort {#Sec3}
------------

We performed a single-center, observational study of consecutive non-diabetes patients with ACS performed PCI in the First Affiliated Hospital of Medical College of Xi'an Jiaotong University from December 2010 to December 2011, which included unstable angina, non-ST-segment elevation myocardial infarction (NSTEMI), and ST-segment elevation MI (STEMI).

They all performed PCI using standard techniques after Qualitative and quantitative coronary angiographic analyses. All procedural decisions, including device selection and adjunctive pharmacotherapy, were made at the discretion of experienced interventional cardiologists according to 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention \[[@CR9]\]. The diagnostic criteria of DM were: HbA1c ≥6.5 %, FPG ≥7.0 mmol/L, 2-h PG ≥11.1 mmol/L according to 2010 ADA Diagnosis and classification of diabetes mellitus \[[@CR10]\].

Exclusion criteria were history of DM, treatment with diabetes drugs, HbA1c content ≥6.5 % on admission, no treatment with PCI, advanced liver disease, renal failure, cancer, valvular heart disease, stroke, idiopathic dilated or hypertrophic cardiomyopathy, peripheral arterial disease, pregnancy, receiving anti-inflammatory drugs, acute or chronic infections or autoimmune disease, and blood or thyroid disease.

The study complied with the Declaration of Helsinki and was approved by the ethics committee of the hospital. Written informed consent was obtained from all patients.

Demographic and clinical data {#Sec4}
-----------------------------

Main demographic data, cardiovascular risk factors and cardiovascular drugs received were obtained from medical records. Current smokers were defined as having smoked more than 100 cigarettes during their lifetime and still smoking in the past 30 days. Hypertension was defined as resting blood pressure ≥140/90 mmHg at two different visits or receiving hypertension drugs. Previous MI was based on a history of acute MI (AMI) or with signs of an infarction outside the area of the index infarction.

Blood samples {#Sec5}
-------------

Peripheral blood was sampled from patients in a fasting state the morning following the admission day. Venous plasma concentrations of glucose, lipids, lipoproteins, serum creatinine, N-terminal pro-B-type natriuretic peptide (NT-proBNP), white blood cell, platelet count (PLT), Neutrophile count, Monocyte count and HbA1c content (normal values 4--6 %) were determined in the biochemistry department using standard biochemical techniques for the hospital. We calculated estimated glomerular filtration rate as (ml min^−1^ 1.73 m^−2^) = 194 × (serum creatinine)^−1.094^ × (age)^−0.287^(× 0.739 if female).

They all performed Echocardiography for left ventricle function through left ventricle ejection fraction (LVEF).

Calculation of GRACE risk score {#Sec6}
-------------------------------

The GRACE risk prediction tool was previously described \[[@CR11]\]. The score is derived from several variables (age, heart rate, systolic blood pressure, creatinine level, congestive heart failure, in-hospital percutaneous coronary intervention, in-hospital coronary aortic bypass grafting, history of MI, ST-segment depression, and elevated cardiac enzyme/marker levels) and calculated for each patient. The GRACE risk score was originally designed to predict post-discharge 6 month mortality and had been shown to provide good discrimination of mortality up to 4 years after an ischemic event \[[@CR12]--[@CR14]\].

Outcomes and follow-up {#Sec7}
----------------------

All-cause death and nonfatal MI were defined as MACEs. All patients were followed up by interview or telephone in our hospital, and the end of follow-up was the date of the first MACE occurrence obtained by reviewing hospital records. Some patients were followed up until December 2014.

Statistical analysis {#Sec8}
--------------------

Data were analyzed by use of SPSS 19.0 for Windows (SPSS Inc., Chicago, IL, USA). Continuous variables were expressed as mean ± SD. Categorical variables were expressed as frequency and percentage. The Kolmogorov--Smirnov test was used to assess normal distribution of quantitative variables. Independent samples *t* test was used to compare two groups, and categorical variables were compared by Chi square test. One-way ANOVA was used to compare multiple groups. To limit the influence of extreme observations, NT-proBNP was natural logarithmically transformed to obtain Ln NT-proBNP. Correlation was analyzed by Spearman's rank correlation. Univariate and multivariate survival analyses involved Cox regression analysis. To assess the prognostic value of HbA1c content, Kaplan--Meier survival curves were used. Additionally, the incremental predictive value resulting from adding HbA1c variable to GRACE risk score was analyzed in the validation set using several measures of improvement in discrimination: increase in the area under the receiver-operating characteristic (ROC) curve (AUC), as well as integrated discrimination improvement (IDI), and continuous net reclassification improvement (NRI). DeLong's test was used to compare the AUC from each of models \[[@CR15]\], which were analyzed by use of MedCalc Version 11.4.2.0. The IDI was equal to the increase in discrimination slope defined as the mean difference in predicted risks between those with and without events. The continuous NRI was a non-parametric analogue of the IDI and equals twice the difference in probabilities of upward reclassification for events minus for non-events \[[@CR16]\], which were analyzed by use of SAS 9.2 (SAS Institute Inc., Cary, NC, USA).

All probability values were two-tailed. *P* \< 0.05 was considered statistically significant.

Results {#Sec9}
=======

Baseline characteristics of patients {#Sec10}
------------------------------------

During a median of 42.3 months (interquartile range 39.3--44.2 months), 16 (2.9 %) were lost to follow-up. In the study, a total of 533 consecutive patients (a mean age of 59.96 ± 12.65 years, 67.7 % man) included 203 unstable angina, 95 NSTEMI and 235 STEMI, the HbA1c content in each type of ACS was respectively 5.588 ± 0.45 %, 5.598 ± 0.51 %, 5.610 ± 0.45 %, in which there was no statistical differences (*p* = 0.878). Among the 533 patients, 69 (12.9 %) experienced a MACE, including 51 (9.6 %) all-cause deaths and 18 (3.4 %) nonfatal myocardial infarction cases. The event rate of each type of ACS was 9.85 % (20/203), 15.78 % (15/95), 14.46 % (34/235). All patients were segregated into three groups by tertiles of baseline HbA1c content (≤5.4 %, 5.5--5.8 %, 5.9--6.4 %). Baseline characteristics were shown in Additional file [1](#MOESM1){ref-type="media"}: Table S1: Patients in the higher HbA1c levels more often had a prior history of PCI, were lower ejection fraction, eGFR level, as well as higher in Monocyte count and LnNT-ProBNP.

Clinical characteristics of patients with and without MACEs {#Sec11}
-----------------------------------------------------------

Patients with MACEs were elderly, had more frequent prior history of hypertension, prior history of MI, prior history of PCI and were higher LnNT-ProBNP, PLT, monocyte count, GRACE score and HbA1c content as well as lower ejection fraction compared to patients without MACEs (Table [1](#Tab1){ref-type="table"}). We carried out the correlation analysis between the GRACE risk score and HbA1c levels as continuous variables and showed that GRACE score was positively correlated with HbA1c content (R = 0.192, *p* \< 0.001).Table 1Characteristics of non-DM patients with ACS undergoing PCI with or without major adverse cardiac events (MACEs)VariableAll patients (n = 533)With MACE (n = 69)Without MACE (n = 464)*p* valueAge (year)59.96 ± 12.6564.58 ± 11.4359.27 ± 12.69*0.001*Sex Male361 (67.7)47 (68.1)314 (67.7)0.941BMI (kg/m^2^)24.11 ± 2.7024.60 ± 2.9624.04 ± 2.650.111Hypertension195 (36.6)40 (58.0)155 (33.4)*\<0.001*Smoking333 (62.5)48 (69.6)285 (61.4)0.192Prior MI37 (6.9)13 (18.8)24 (5.2)*\<0.001*Prior PCI24 (4.5)7 (10.1)17(3.7)*0.015*DBP (mmHg)77.94 ± 13.0077.88 ± 12.4077.95 ± 13.110.967SBP (mmHg)125.53 ± 20.02126.35 ± 21.78125.41 ± 19.770.716Heart rate (bpm)75.36 ± 13.2777.12 ± 13.5075.10 ± 13.240.240eGFR (mL min^−1^ 1.73 m^−2^)88.60 ± 35.5087.05 ± 37.3188.83 ± 35.260.697FBS (mmol/L)6.37 ± 1.826.28 ± 1.356.39 ± 1.880.652TC (mmol/L)3.92 ± 1.083.94 ± 0.923.92 ± 1.100.926TG (mmol/L)1.62 ± 1.001.47 ± 1.071.65 ± 0.990.171HDL (mmol/L)1.02 ± 0.251.04 ± 0.261.02 ± 0.250.541LDL (mmol/L)2.28 ± 0.742.30 ± 0.752.27 ± 0.740.774Apo A1 (g/L)1.08 ± 0.181.08 ± 0.221. 08 ± 0.180.894Apo B (g/L)0.77 ± 0.230.76 ± 0.220.77 ± 0.230.904LVEF (%)54.26 ± 12.3449.68 ± 12.2354.94 ± 12.15*0.001*NT-proBNP (pg/mL)5.86 ± 1.606.30 ± 1.825.79 ± 1.56*0.013*PLT count (10^9^/L)192.81 ± 68.17212.67 ± 82.73189.86 ± 65.32*0.009*WBC count (10^9^/L)8.05 ± 3.238.38 ± 3.568.00 ± 3.180.366Monocyte count (10^9^/L)0.57 ± 0.320.65 ± 0.450.55 ± 0.30*0.021*Neutrophile count (10^9^/L)5.92 ± 3.146.36 ± 3.215.85 ± 3.130.213HbA1c content (%)5.60 ± 0.465.90 ± 0.335.56 ± 0.46*\<0.001*GRACE score110.47 ± 27.13131.45 ± 24.40107.35 ± 26.13*\<0.001*Medication at discharge Aspirin524 (98.3)66 (95.7)458 (98.7)0.066 Clopidogrel527 (98.9)68 (98.5)459 (98.9)0.785 Statins430 (80.7)58 (84.1)372 (80.2)0.446 ACEI/ARB389 (73.0)46 (66.7)343 (73.9)0.205 β-blockers347 (65.1)42 (60.9)305 (65.7)0.429Data are mean ± SD or n (%)*BMI* body mass index, *Prior MI* prior myocardial infarction, *Prior PCI* prior percutaneous coronary intervention, *SBP* systolic blood pressure, *DBP* diastolic blood pressure, *eGFR* estimated glomerular filtration rate, *FBS* fasting blood sugar, *TC* total cholesterol, *TG* triglycerides, *HDL-C* high-density lipoprotein cholesterol, *LDL-C* low-density lipoprotein cholesterol, *Apo-A1* apolipoprotein A1, *Apo-B* apolipoprotein B, *NT-proBNP* N-terminal pro-B-type natriuretic peptide, *PLT* platelets, *LVEF* left ventricle ejection fraction, *WBC* white blood cell count, *ACEI* angiotensin-converting enzyme inhibition, *ARB* angiotensin receptor blocker, *HbA1c* hemoglobin A1c, *GRACE score* Global Registry of Acute Coronary Events (GRACE) score

HbA1c content as an independent predictor of MACE occurrence {#Sec12}
------------------------------------------------------------

On univariate Cox analysis, significant predictors of a MACE were age, hypertension, prior MI,prior PCI, LVEF, LnNT-ProBNP, PLT, monocyte count, HbA1c content and GRACE score (Table [2](#Tab2){ref-type="table"}). On multivariate Cox analysis, HbA1c content was a significant and independent predictor of a MACE \[hazard ratio (HR) 3.530; 95 % confidence interval (95 % CI) 1.927--6.466; *p* \< 0.001\] as was GRACE score (HR 1.030; 95 % CI 1.020--1.0403; *p* \< 0.001) (Table [3](#Tab3){ref-type="table"}). The cumulative risk of a MACE generally increased with elevated HbA1c content by Kaplan--Meier analysis (log-rank 33.906, *p* \< 0.001; Fig. [1](#Fig1){ref-type="fig"}).Table 2Univariate Cox analysis for MACEsVariableHR95 % CI*p* valueAge (per 1 year)1.0321.012--1.052*0.001*Male (vs. female)0.9100.480--1.7250.772BMI (per 1 kg/m^2^)1.0710.984--1.1660.111Hypertension2.5711.594--4.148*\<0.001*Smoking1.4380.861--2.4020.165Prior MI3.4541.888--6.319*\<0.001*Prior PCI2.8391.299--6.206*0.009*DBP (per 1 mmHg)1.0000.982--1.0180.976SBP (per 1 mmHg)1.0020.991--1.0140.716Heart rate (per 1 mmHg)1.0100.993--1.0260.240eGFR (per 1 mL min^−1^ 1.73 m^−2^)0.9980.992--1.0050.647FBS (per 1 mmol/L)0.9760.856--1.1120.712TC (per 1 mmol/L)1.0130.820--1.2520.903TG (per 1 mmol/L)0.7870.566--1.0940.153HDL (per 1 mmol/L)1.3550.543--3.3800.515LDL (per 1 mmol/L)1.0480.767--1.4320.766Apo A1 (per 1 g/L)0.9260.248--3.4510.908Apo B (per 1 g/L)0.9550.338--2.6970.931LVEF (per 1 %)0.9650.945--0.985*0.001*NT-proBNP (per 1 ln unit)1.2361.052--1.451*0.010*PLT count (per 10^9^/L)1.0041.001--1.006*0.006*WBC count (per 10^9^/L)1.0350.966--1.1090.326Monocyte count (per 10^9^/L)2.1411.189--3.855*0.011*Neutrophile count (per 10^9^/L)1.0460.976--1.1200.202HbA1c content (per 1 %)5.3422.968--9.613*\<0.001*GRACE score (per 1)1.0331.024--1.043*\<0.001HR* hazard ratio, *95* *% CI* 95 % confidence intervalTable 3Multivariate Cox analysis for MACEsVariableHR95 % CI*p* valueHbA1c (per 1 %)3.5301.927--6.466\<0.001GRACE score (per 1)1.0301.020--1.040\<0.001Hypertension1.9321.185--3.1480.008Prior MI2.3721.284--4.3280.006LVEF (per 1 %)0.9720.952--0.9920.006PLT (per 10^9^/L)1.1161.023--1.2180.013*HR* hazard ratio, *95* *% CI* 95 % confidence intervalFig. 1Kaplan--Meier analysis of major adverse cardiac events (MACEs) based on hemoglobin A1c (HbA1c) content. The 533 patients were divided by tertiles of HbA1c content: ≤5.4 %, 5.5--5.8 %, and 5.9--6.4 %. Risk of a MACE increased with increasing tertile of HbA1c content (log-rank test 33.906, *p* \< 0.001)

Effect of HbA1c content and GRACE score combined on MACE occurrence {#Sec13}
-------------------------------------------------------------------

Since both HbA1c content and GRACE score were independent risk factors of a MACE, we assessed the effect of their combination on predicting long-term risk of MACE occurrence. The AUC increased from 0.75 (95 % CI 0.69--0.82) for GRACE score alone to 0.80 (95 % CI 0.75--0.85) for GRACE score adjustment by HbA1c content (difference in the AUCs, 0.05; z value 2.521, *p* = 0.012) (Fig. [2](#Fig2){ref-type="fig"}). Addition of HbA1c content improved GRACE score alone model discrimination, which was confirmed by the IDI and the continuous, category-free NRI (\>0). The IDI for HbA1c content was 0.055 (95 % CI 0.035--0.075, *P* \< 0.001), suggesting further average separation of events from non-events by the HbA1c; the NRI (\>0) for HbA1c content was 0.70, (95 % CI 0.47--0.94, *P* \< 0.001), with events contributing 0.42 and non-events 0.28 (Table [4](#Tab4){ref-type="table"}), showing that the HbA1c content led to a significant net reclassification of patients^,^ risk in the appropriate directions.Fig. 2Receiver operating characteristic (ROC) curve analysis. The addition of HbA1c content to the GRACE score as continuous variables could improve the predictive power for long-term MACEs (area under the ROC curve for GRACE score alone, 0.75; combined with HbA1c content, 0.80; z value 2.521, *p* = 0.012)Table 4Statistics for model improvement with the addition of HbA1c content*p* valueEvents, n (%)69 (12.9)Nonevents, n (%)464 (87.1)Continuous NRI (%) cNRI~event~42 cNRI~nonevent~28 cNRI70 (95 % CI 47--94)*\<0.001* IDI statistics IDI0.055 (95 % CI 0.035--0.075)*\<0.001*AUC GRACE risk score0.75 (95 % CI 0.69--0.82) GRACE + HbA1c0.80 (95 % CI 0.75--0.85) Difference0.05*0.01295* *% CI* 95 % confidence interval, *IDI* integrated discrimination improvement, *NRI* net reclassification improvement, *cNRI* continuous net reclassification improvement

Discussion {#Sec14}
==========

Management decisions in ACS should be based on risk stratification of patients. The GRACE score provides validated prognostic information for MACEs in ACS patients \[[@CR12], [@CR14]\]. In accordance with previous research results, the GRACE score could independently predict a MACE in our ACS patients without DM undergoing PCI. However, the AUC with the GRACE score alone was only 0.75, which might be due to some potential risk factors not fully captured by the scoring system. Growing epidemiological evidence supports that HbA1c content in the general population and in patients with and without diabetes is an independent risk factor of cardiovascular events including MI \[[@CR6], [@CR8], [@CR17]\]. However, HbA1c content has not been considered with the GRACE scoring system in previous research. In our patients, the GRACE score increased with increasing HbA1c content at baseline, and the 2 variables were correlated. Moreover, the GRACE score adjustment by HbA1c content on admission enhanced the predictive value for ACS patients without DM undergoing PCI (AUC increased from 0.75 for GRACE score alone to 0.80 for GRACE score plus HbA1c).To better assess the improvement in discrimination of GRACE score adjustment by HbA1c variable, we used new statistical metrics \[IDI and a category-free, continuous NRI (\>0)\], and IDI for HbA1c showed further average separation of events from non-events by the HbA1c; Using the a category-free, continuous NRI (\>0),we fund that a net 28 % of the patients without events were reclassified into lower risk and that a net 42 % of patients with events were reclassified into higher risk. The category-free, continuous NRI (\>0) thus reached an impressive 0.70, which suggested that the HbA1c content led to a significant net reclassification of patients^,^ risk in the appropriate directions.

In the present study, the long-term event rate seems low compared previous researches. It may attribute to followed reasons. Firstly, the enrolled patients were non-DM, which were lower in the cardiovascular events rate than that in patients with diabetic mellitus, especially in the patients of poor nocturnal glycemic control \[[@CR18]\]. Secondly, Recent some reports have shown ethnic differences effect the MACE occurrence rate after PCI not only between African Americans and whites \[[@CR19], [@CR20]\],but also in Asian subpopulations, such as compared to Indian, Chinese patients have lower Major Adverse Cardiovascular Events \[[@CR21]--[@CR23]\]. In addition, our results was comparable compared with the MACE rate documented by Clinical Pathways for Acute Coronary Syndromes in China (CPACS) study \[[@CR24], [@CR25]\].

Although some research had found that higher level of admission glucose predict a worse prognosis including mortality and MI in ACS patients \[[@CR26]--[@CR28]\], recent studies showed that the prediction value of admission glucose was not improved by combining GRACE score \[[@CR29]\]. As different from admission glucose, HbA1c is an indicator of general glycometabolic state and is minimally affected by acute stress and also acute glucose management. Increased HbA1c content was not only showed as a indictor of complications including ACS \[[@CR30]\] but also a predictor of long-term survival in ACS patients with and without DM \[[@CR31]--[@CR33]\]. Whether the HbA1c content in ACS patients without DM undergoing PCI could be an independent predictor of cardiovascular events is uncertain. In our study, HbA1c content at baseline was higher in patients with than without a MACE, and HbA1c content could independently predict a long-term MACE in ACS patients without DM undergoing PCI. Furthermore, we found that the predictive value on MACE of adding HbA1c on the top of GRACE score system.

Researches have found that C-reactive protein \[[@CR34]\], NT-proBNP \[[@CR35]\], erythrocyte fatty acids \[[@CR36]\], growth differentiation factor-15 \[[@CR37]\], cystatin C \[[@CR38]\], dikkopf \[[@CR39]\], RDW/PDW \[[@CR40]\], high-sensitivity troponin \[[@CR41]\], mean platelet volume(MPV) \[[@CR42]\] and other factors add value to a scoring system for predicting adverse cardiovascular events after ACS. We found that GRACE score and baseline HbA1c content were positively correlated, and their combination improved the predictive value. Whether this combination can improve the outcome of ACS patients with DM needs further comprehensive investigation in clinical practice.

Limitations {#Sec15}
===========

The number of patients in the cohort was relatively small. Therefore, these findings need to be verified by multicenter and larger cohort studies. In addition, this study was limited to Chinese subjects, so conclusions for other ethnic groups are cautioned.

Conclusions {#Sec16}
===========

HbA1c content measured in ACS patients without DM undergoing PCI could predict a MACE and was positively related with GRACE score. The combination of the two factors may improve on risk stratification of ACS patients without DM undergoing PCI.

Additional file {#Sec17}
===============

Additional file 1:**Table S1.** Baseline characteristics of 533 non-diabetes mellitus (DM) patients with acute coronary syndrome (ACS) undergoing Percutaneous Coronary Intervention (PCI) by tertiles of HbA1c content.

BMI

:   body mass index

Prior MI

:   prior myocardial infarction

Prior PCI

:   prior percutaneous coronary intervention

SBP

:   systolic blood pressure

DBP

:   diastolic blood pressure

eGFR

:   estimated glomerular filtration rate

FBS

:   fasting blood sugar

TC

:   total cholesterol

TG

:   triglycerides

HDL-C

:   high-density lipoprotein cholesterol

LDL-C

:   low-density lipoprotein cholesterol

Apo-A1

:   apolipoprotein A1

Apo-B

:   apolipoprotein B

NT-proBNP

:   N-terminal pro-B-type natriuretic peptide

PLT

:   platelets

LVEF

:   left ventricle ejection fraction

WBC

:   white blood cell count

ACEI

:   angiotensin-converting enzyme inhibition

ARB

:   angiotensin receptor blocker

ANOVA

:   one-way analysis of variance

HbA1c

:   HemoglobinA1c

MACEs

:   major adverse cardiac events

DM

:   diabetes mellitus

ACS

:   acute coronary syndrome

AUC

:   the receiver-operating characteristic curve

ROC

:   receiver-operating characteristic

GRACE

:   the Global Registry of Acute Coronary Events

NSTEMI

:   non-ST-segment elevation myocardial infarction

STEMI

:   ST-segment elevation MI

IDI

:   integrated discrimination improvement

NRI

:   net reclassification improvement
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